FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H.
Iwamoto S, et al. Among authors: sakamoto j.
Ann Oncol. 2015 Jul;26(7):1427-33. doi: 10.1093/annonc/mdv197. Epub 2015 Apr 23.
Ann Oncol. 2015.
PMID: 25908603
Free PMC article.
Clinical Trial.